Dublin, May 15, 2023 (GLOBE NEWSWIRE) -- The "Erythropoietin Drugs Market Size, Share & Trends Analysis Report By Type (Biologics, Biosimilars) By Product (Erythropoietin, Darbepoetin-alfa), By Application (Cancer, Renal Disease, Neurology), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030.
Companies Mentioned
- Johnson & Johnson Services, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- LG Chem
- Biocon
- Intas Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd
The slow growth can be attributed to the patent expiry of multiple biologics, increasing approval and penetration of biosimilars, and declining prices. For instance, PanGen Biotech Inc. is developing Erisa (PDA10). This erythropoietin biosimilar drug is under phase 3 clinical trial to check the safety and efficacy of the drug in patients with anemia.
The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.
Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.
Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others.
In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.
Erythropoietin Drugs Market Report Highlights
- By type, the biologics segment accounted for the largest share of the market in 2022. This can be attributed to the availability of FDA-approved EPO biologics for the treatment of cancer-induced anemia and CKD patients.
- Based on product, the erythropoietin segment dominated the EPO drugs market in 2022 owing to the higher number of approved products and higher prescription rate of erythropoietin.
- The renal diseases segment dominated the EPO drugs market in 2022. The high prevalence of CKD and the high prescription rate of EPO drugs are major factors contributing to the dominance of this segment. According to the National Kidney Foundation (NKF), 10% of the total population is affected by chronic kidney disease (CKD) worldwide.
- North America dominated the global market in 2022 owing to factors such as late approval and lower penetration of biosimilars in the market
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 126 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $6.87 Billion |
| Forecasted Market Value (USD) by 2030 | $7.8 Billion |
| Compound Annual Growth Rate | 1.5% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping for Type, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of chronic diseases
3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
3.3.2 Market Restraint Analysis
3.3.2.1 Patent expiration of branded drugs
3.4 Market Analysis Tools
3.5 Pipeline Analysis
Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)
4.1 Erythropoietin Drugs Market: Type Movement Analysis
4.1.1 Biologics
4.1.1.1 Biologics Market Estimates and Forecast, 2018 - 2030 (USD Million)
4.1.2 Biosimilars
4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)
5.1 Erythropoietin Drugs Market: Product Movement Analysis
5.1.1 Erythropoietin
5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.1.2 Darbepoetin-alfa
5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)
6.1 Erythropoietin Drugs Market: Application Movement Analysis
6.1.1 Cancer
6.1.1.1 Cancer Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
6.1.2 Renal Diseases
6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.1.3 Neurology
6.1.3.1 Neurology Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 New Product Launch
8.1.2 Merger and Acquisition
8.1.3 Licensing Agreements
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of Key Distributors and Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Key Company Market Share Analysis, 2022
8.4.2 Company Market Position Analysis
8.4.3 Heat Map Analysis
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.5.2 Regional Network Map
8.6 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/lq0kft
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
